Oramed Pharmaceuticals Selected to Present at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL,

Oramed Pharmaceuticals Selected to Present at the 73rd Scientific Sessions of
      the American Diabetes Association in Chicago, IL, June 21-25, 2013

PR Newswire

JERUSALEM, March 21, 2013

JERUSALEM, March 21, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that its abstract,
titled "Dose response to oral insulin capsules in fasting, healthy subjects,"
has been selected for a poster presentation at the 73^rd Scientific Sessions
of the American Diabetes Association, being held on June 21-25, 2013, in
Chicago, IL, USA. In addition, the work was selected to be showcased in the
Scientific Session's Innovative Oral Agents-Innovative Discoveries Guided
Audio Poster Tour, to be held on Monday, June 24, 2013. This 50-min tour
presents and provides a moderated discussion of 7-8 posters in efforts to
expose meeting attendees to particularly novel or recent developments in the

About the American Diabetes Association (ADA) Scientific Sessions

The ADA's Scientific Sessions brings together scientists and health care
professionals from around the world who are involved in diabetes research and
care. The five-day meeting features the most timely and significant advances
in the prevention, diagnosis, and treatment of diabetes. The program is
organized into eight distinctive theme areas and includes presentation by
world-renowned diabetes experts.

For more information on the ADA, please refer to their website:

More information on the Scientific Sessions can be found here.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching Phase 2 clinical trials under U.S. IND, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

The company's fact sheet can be viewedhere.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and federal securities laws. For
example, we are using forward-looking statements when we discuss our
approaching of phase 2 clinical trials. These forward-looking statements are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.